Penumbra, Inc. Reports Third Quarter 2021 Financial Results
Penumbra, Inc. (NYSE: PEN) reported strong financial results for Q3 2021, with a revenue increase of 25.8% year-over-year, reaching $190.1 million. Vascular product sales surged 40.3% to $105.5 million, while neuro products rose 11.5% to $84.7 million. Gross profit improved to 63.1% of total revenue, totaling $119.9 million. Operating income shifted to $8.8 million from a loss of $20.2 million a year earlier. The company also raised its 2021 revenue guidance to between $735 million to $740 million, reflecting a growth of 31% to 32% over 2020.
- Revenue increased to $190.1 million, up 25.8% YoY.
- Vascular product sales grew 40.3% to $105.5 million.
- Gross profit margin improved to 63.1%, totaling $119.9 million.
- Operating income of $8.8 million, a turnaround from a loss last year.
- Raised full-year 2021 revenue guidance to $735-$740 million.
- SG&A expenses increased to $94.4 million from $76.2 million YoY.
ALAMEDA, Calif., Nov. 3, 2021 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the third quarter ended September 30, 2021.
- Revenue of
$190 .1 million in the third quarter of 2021, an increase of25.8% , or25.6% in constant currency1, compared to the third quarter of 2020.
Third Quarter 2021 Financial Results
Total revenue increased to
Gross profit was
Total operating expenses for the third quarter of 2021 were
Operating income for the third quarter of 2021 was
1See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures.
Updated Full Year 2021 Financial Outlook
The Company is increasing its guidance for 2021 total revenue to be in the range of
Webcast and Conference Call Information
Penumbra, Inc. will host a conference call to discuss the third quarter 2021 financial results after market close on Wednesday, November 3, 2021 at 4:30 PM Eastern Time. The conference call can be accessed live over the phone by dialing (833) 350-1434 for domestic and international callers (conference id: 2341689), or the webcast can be accessed on the "Events" section under the "Investors" tab of the Company's website at: www.penumbrainc.com. The webcast will be available on the Company's website for at least two weeks following the completion of the call.
About Penumbra
Penumbra, Inc., headquartered in Alameda, California, is a global healthcare company focused on innovative therapies. Penumbra designs, develops, manufactures and markets novel products and has a broad portfolio that addresses challenging medical conditions in markets with significant unmet need. Penumbra supports healthcare providers, hospitals and clinics in more than 100 countries. The Penumbra logo is a trademark of Penumbra, Inc. For more information, visit www.penumbrainc.com.
Non-GAAP Financial Measures
In addition to financial measures prepared in accordance with U.S. generally accepted accounting principles ("GAAP"), the Company uses the following non-GAAP financial measures in this press release: a) non-GAAP net income (loss) and non-GAAP diluted earnings per share ("EPS") and b) constant currency.
Non-GAAP net income (loss) and non-GAAP diluted EPS. The Company defines non-GAAP net income (loss) as net income (loss) attributable to Penumbra, Inc. excluding the effects of the impairment loss on an indefinite-lived intangible asset and the excess tax benefits associated with share-based compensation arrangements. The Company defines non-GAAP diluted EPS as GAAP diluted EPS, excluding the effects of the same items above.
Constant Currency. The Company's constant currency revenue disclosures estimate the impact of changes in foreign currency rates on the translation of the Company's current period revenue as compared to the applicable comparable period in the prior year. This impact is derived by taking the current local currency revenue and translating it into U.S. dollars based upon the foreign currency exchange rates used to translate the local currency revenue for the applicable comparable period in the prior year, rather than the actual exchange rates in effect during the current period. It does not include any other effect of changes in foreign currency rates on the Company's results or business.
Full reconciliation of these non-GAAP measures to the most comparable GAAP measures is set forth in the tables below.
Our management believes the non-GAAP financial measures disclosed in this press release are useful to investors in assessing the operating performance of our business and provide meaningful comparisons to prior periods and thus a more complete understanding of our business than could be obtained absent this disclosure. Specifically, we consider the change in constant currency revenue as a useful metric as it provides an alternative framework for assessing how our underlying business performed excluding the effect of foreign currency rate fluctuations. We consider non-GAAP net income (loss) and non-GAAP diluted EPS useful metrics as they provide an alternative framework for assessing how our underlying business performed excluding the impairment loss on an indefinite-lived intangible asset and the excess tax benefits associated with share-based compensation arrangements.
The non-GAAP financial measures included in this press release may be different from, and therefore may not be comparable to, similarly titled measures used by other companies. These non-GAAP measures should not be considered in isolation or as alternatives to GAAP measures. We urge investors to review the reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures included in this press release, and not to rely on any single financial measure to evaluate our business.
Forward-Looking Statements
Except for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. Factors that could cause actual results to differ from those projected include, but are not limited to: the impact of the COVID-19 pandemic on our business, results of operations and financial condition; failure to sustain or grow profitability or generate positive cash flows; failure to effectively introduce and market new products; delays in product introductions; significant competition; inability to further penetrate our current customer base, expand our user base and increase the frequency of use of our products by our customers; inability to achieve or maintain satisfactory pricing and margins; manufacturing difficulties; permanent write-downs or write-offs of our inventory; product defects or failures; unfavorable outcomes in clinical trials; inability to maintain our culture as we grow; fluctuations in foreign currency exchange rates; potential adverse regulatory actions; and the potential impact of any acquisitions, mergers, dispositions, joint ventures or investments we may make. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on February 23, 2021. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change.
Penumbra, Inc. | ||||||||
Condensed Consolidated Balance Sheets | ||||||||
(unaudited) | ||||||||
(in thousands) | ||||||||
September 30, 2021 | December 31, 2020 | |||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 66,290 | $ | 69,670 | ||||
Marketable investments | 200,637 | 195,162 | ||||||
Accounts receivable, net | 120,074 | 114,608 | ||||||
Inventories | 258,316 | 219,527 | ||||||
Prepaid expenses and other current assets | 22,670 | 18,735 | ||||||
Total current assets | 667,987 | 617,702 | ||||||
Property and equipment, net | 56,632 | 48,169 | ||||||
Operating lease right-of-use assets | 133,552 | 41,192 | ||||||
Finance lease right-of-use assets | 36,845 | 38,065 | ||||||
Intangible assets, net | 9,490 | 10,639 | ||||||
Goodwill | 7,911 | 8,372 | ||||||
Deferred taxes | 49,454 | 50,139 | ||||||
Other non-current assets | 11,370 | 8,705 | ||||||
Total assets | $ | 973,241 | $ | 822,983 | ||||
Liabilities and Stockholders' Equity | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 13,679 | $ | 14,109 | ||||
Accrued liabilities | 93,222 | 85,795 | ||||||
Current operating lease liabilities | 7,531 | 4,697 | ||||||
Current finance lease liabilities | 1,627 | 1,331 | ||||||
Total current liabilities | 116,059 | 105,932 | ||||||
Non-current operating lease liabilities | 138,169 | 44,183 | ||||||
Non-current finance lease liabilities | 26,775 | 27,066 | ||||||
Other non-current liabilities | 7,635 | 8,014 | ||||||
Total liabilities | 288,638 | 185,195 | ||||||
Stockholders' equity: | ||||||||
Common stock | 36 | 36 | ||||||
Additional paid-in capital | 621,457 | 598,299 | ||||||
Accumulated other comprehensive (loss) income | (1,093) | 2,541 | ||||||
Retained earnings | 70,539 | 40,622 | ||||||
Total Penumbra, Inc. stockholders' equity | 690,939 | 641,498 | ||||||
Non-controlling interest | (6,336) | (3,710) | ||||||
Total stockholders' equity | 684,603 | 637,788 | ||||||
Total liabilities and stockholders' equity | $ | 973,241 | $ | 822,983 | ||||
Penumbra, Inc. | ||||||||||||||||
Condensed Consolidated Statements of Operations | ||||||||||||||||
(unaudited) | ||||||||||||||||
(in thousands, except share and per share amounts) | ||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
2021 | 2020 | 2021 | 2020 | |||||||||||||
Revenue | $ | 190,117 | $ | 151,076 | $ | 543,579 | $ | 393,514 | ||||||||
Cost of revenue | 70,205 | 60,153 | 193,644 | 149,652 | ||||||||||||
Gross profit | 119,912 | 90,923 | 349,935 | 243,862 | ||||||||||||
Operating expenses: | ||||||||||||||||
Research and development | 16,734 | 34,923 | 52,548 | 70,594 | ||||||||||||
Sales, general and administrative | 94,397 | 76,158 | 264,831 | 210,465 | ||||||||||||
Total operating expenses | 111,131 | 111,081 | 317,379 | 281,059 | ||||||||||||
Income (loss) from operations | 8,781 | (20,158) | 32,556 | (37,197) | ||||||||||||
Interest income, net | 138 | 413 | 917 | 820 | ||||||||||||
Other (expense) income, net | (1,137) | 14 | (3,021) | (1,130) | ||||||||||||
Income (loss) before income taxes | 7,782 | (19,731) | 30,452 | (37,507) | ||||||||||||
(Benefit from) provision for income taxes | (249) | (9,855) | 3,196 | (15,618) | ||||||||||||
Consolidated net income (loss) | $ | 8,031 | $ | (9,876) | $ | 27,256 | $ | (21,889) | ||||||||
Net loss attributable to non-controlling interest | (819) | (1,061) | (2,661) | (2,539) | ||||||||||||
Net income (loss) attributable to Penumbra, Inc. | $ | 8,850 | $ | (8,815) | $ | 29,917 | $ | (19,350) | ||||||||
Net income (loss) attributable to Penumbra, Inc. per share: | ||||||||||||||||
Basic | $ | 0.24 | $ | (0.24) | $ | 0.82 | $ | (0.54) | ||||||||
Diluted | $ | 0.24 | $ | (0.24) | $ | 0.80 | $ | (0.54) | ||||||||
Weighted average shares outstanding: | ||||||||||||||||
Basic | 36,617,961 | 36,207,716 | 36,532,822 | 35,568,591 | ||||||||||||
Diluted | 37,611,355 | 36,207,716 | 37,592,095 | 35,568,591 | ||||||||||||
Penumbra, Inc. | ||||||||||||||||||||||||||||||||
Reconciliation of GAAP Net Income (Loss) and GAAP Diluted EPS to Non-GAAP Net Income (Loss) and Non-GAAP Diluted EPS1 | ||||||||||||||||||||||||||||||||
(unaudited) | ||||||||||||||||||||||||||||||||
(in thousands, except per share amounts) | ||||||||||||||||||||||||||||||||
Three Months Ended | Three Months Ended | Nine Months Ended | Nine Months Ended | |||||||||||||||||||||||||||||
Net | Diluted | Net (loss) | Diluted | Net | Diluted | Net (loss) | Diluted | |||||||||||||||||||||||||
GAAP net income (loss) | $ | 8,850 | $ | 0.24 | $ | (8,815) | $ | (0.24) | $ | 29,917 | $ | 0.80 | $ | (19,350) | $ | (0.54) | ||||||||||||||||
GAAP net (loss) income includes the effect of the | ||||||||||||||||||||||||||||||||
Impairment loss on indefinite-lived intangible | — | — | — | — | — | — | 2,500 | 0.07 | ||||||||||||||||||||||||
Excess tax benefits related to stock compensation | (4,244) | (0.12) | (7,386) | (0.21) | (7,431) | (0.20) | (10,188) | (0.29) | ||||||||||||||||||||||||
Non-GAAP net income (loss) | $ | 4,606 | $ | 0.12 | $ | (16,201) | $ | (0.45) | $ | 22,486 | $ | 0.60 | $ | (27,038) | $ | (0.76) | ||||||||||||||||
GAAP diluted EPS | $ | 0.24 | $ | (0.24) | $ | 0.80 | $ | (0.54) | ||||||||||||||||||||||||
Non-GAAP diluted EPS | $ | 0.12 | $ | (0.45) | $ | 0.60 | $ | (0.76) | ||||||||||||||||||||||||
Weighted average shares outstanding used to compute: | ||||||||||||||||||||||||||||||||
GAAP diluted EPS | 37,611,355 | 36,207,716 | 37,592,095 | 35,568,591 | ||||||||||||||||||||||||||||
Non-GAAP diluted EPS | 37,611,355 | 36,207,716 | 37,592,095 | 35,568,591 | ||||||||||||||||||||||||||||
____________ | |
1 | See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures. |
Penumbra, Inc. | ||||||||||||||||||||||||||
Reconciliation of Revenue Growth by Geographic Regions to Constant Currency Revenue Growth1 | ||||||||||||||||||||||||||
(unaudited) | ||||||||||||||||||||||||||
(in thousands) | ||||||||||||||||||||||||||
Three Months Ended September 30, | Reported Change | FX Impact | Constant Currency Change | |||||||||||||||||||||||
2021 | 2020 | $ | % | $ | $ | % | ||||||||||||||||||||
United States | $ | 134,834 | $ | 109,656 | $ | 25,178 | 23.0 | % | $ | — | $ | 25,178 | 23.0 | % | ||||||||||||
International | 55,283 | 41,420 | 13,863 | 33.5 | % | (355) | 13,508 | 32.6 | % | |||||||||||||||||
Total | $ | 190,117 | $ | 151,076 | $ | 39,041 | 25.8 | % | $ | (355) | $ | 38,686 | 25.6 | % | ||||||||||||
Nine Months Ended September 30, | Reported Change | FX Impact | Constant Currency Change | |||||||||||||||||||||||
2021 | 2020 | $ | % | $ | $ | % | ||||||||||||||||||||
United States | $ | 383,306 | $ | 283,473 | $ | 99,833 | 35.2 | % | $ | — | $ | 99,833 | 35.2 | % | ||||||||||||
International | 160,273 | 110,041 | 50,232 | 45.6 | % | (5,459) | 44,773 | 40.7 | % | |||||||||||||||||
Total | $ | 543,579 | $ | 393,514 | $ | 150,065 | 38.1 | % | $ | (5,459) | $ | 144,606 | 36.7 | % | ||||||||||||
Penumbra, Inc. | ||||||||||||||||||||||||||
Reconciliation of Revenue Growth by Product Categories to Constant Currency Revenue Growth1 | ||||||||||||||||||||||||||
(unaudited) | ||||||||||||||||||||||||||
(in thousands) | ||||||||||||||||||||||||||
Three Months Ended September 30, | Reported Change | FX Impact | Constant Currency Change | |||||||||||||||||||||||
2021 | 2020 | $ | % | $ | $ | % | ||||||||||||||||||||
Vascular | $ | 105,465 | $ | 75,159 | $ | 30,306 | 40.3 | % | $ | (23) | $ | 30,283 | 40.3 | % | ||||||||||||
Neuro | 84,652 | 75,917 | 8,735 | 11.5 | % | (332) | 8,403 | 11.1 | % | |||||||||||||||||
Total | $ | 190,117 | $ | 151,076 | $ | 39,041 | 25.8 | % | $ | (355) | $ | 38,686 | 25.6 | % | ||||||||||||
Nine Months Ended September 30, | Reported Change | FX Impact | Constant Currency Change | |||||||||||||||||||||||
2021 | 2020 | $ | % | $ | $ | % | ||||||||||||||||||||
Vascular | $ | 295,314 | $ | 180,684 | $ | 114,630 | 63.4 | % | $ | (1,692) | $ | 112,938 | 62.5 | % | ||||||||||||
Neuro | 248,265 | 212,830 | 35,435 | 16.6 | % | (3,767) | 31,668 | 14.9 | % | |||||||||||||||||
Total | $ | 543,579 | $ | 393,514 | $ | 150,065 | 38.1 | % | $ | (5,459) | $ | 144,606 | 36.7 | % | ||||||||||||
____________ | |
1 | See "Non-GAAP Financial Measures" above for important information about our use of constant currency and other non-GAAP measures. |
Investor Relations
Penumbra, Inc.
510-995-2461
investors@penumbrainc.com
Source: Penumbra, Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/penumbra-inc-reports-third-quarter-2021-financial-results-301415587.html
SOURCE Penumbra, Inc.
FAQ
What were Penumbra's financial results for Q3 2021?
How did Penumbra's vascular and neuro product sales perform in Q3 2021?
What is Penumbra's updated revenue guidance for 2021?
What was Penumbra's gross profit margin for Q3 2021?
Did Penumbra report an operating income or loss in Q3 2021?
